Jul 09, 2024

Public workspaceAlbendazole plus Praziquantel versus Albendazole Alone in the Treatment of Neurocysticercosis: A Systematic Review and Meta-Analysis

DOI
https://dx.doi.org/10.17504/protocols.io.dm6gpzypjlzp/v1
  • Luísa Menegaz1,
  • Gabriela Oliveira Caetano1,
  • Jade Lingiardi Altoé2,
  • Laíse ênin Leodoro Silva1,
  • Maria Eduarda Silva1,
  • Artur Menegaz de Almeida1,
  • Ítalo arros Andrade3,
  • Michele Kreuz MD4,
  • Davi Tanajura Costa5
  • 1Federal University of Mato Grosso, Sinop, Brazil;
  • 2Cesumar University , Maringá, Brazil;
  • 3Santo Agostinho University, Vitória da Conquista, Brazil;
  • 4Lutheran University of Brazil, Canoas, Brazil;
  • 5Federal University of Bahia, Bahia, Brazil
Luísa Menegaz
Icon indicating open access to content
QR code linking to this content
DOI: https://dx.doi.org/10.17504/protocols.io.dm6gpzypjlzp/v1
Protocol Citation: Luísa Menegaz, Gabriela Oliveira Caetano, Jade Lingiardi Altoé, Laíse ênin Leodoro Silva, Maria Eduarda Silva, Artur Menegaz de Almeida, Ítalo arros Andrade, Michele Kreuz MD, Davi Tanajura Costa 2024. Albendazole plus Praziquantel versus Albendazole Alone in the Treatment of Neurocysticercosis: A Systematic Review and Meta-Analysis. protocols.io https://dx.doi.org/10.17504/protocols.io.dm6gpzypjlzp/v1
License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License,  which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Protocol status: Working
We use this protocol and it's working
Created: July 08, 2024
Last Modified: July 09, 2024
Protocol Integer ID: 103037
Keywords: neurocysticercosis, albendazole , praziquantel , treatment of neurocysticercosi, preferred treatment for neurocysticercosi, neurocysticercosi, analysis abstract neurocysticercosi, combination therapy of albendazole, parasitic neurological disease, praziquantel versus albendazole alone, greater benefits than albendazole, albendazole alone, albendazole, neglected tropical disease, tropical diseases in the world, intracranial hypertension, eggs of the taenia solium hatch, praziquantel, taenia solium hatch, headache, seizure, disease
Disclaimer
This research has no financial support.

Abstract
Abstract
Neurocysticercosis is a parasitic neurological disease, considered by the World Health Organization (WHO) as one of the most neglected tropical diseases in the world, also being an important public health concern in Brazil. The eggs of the Taenia solium hatch and the larvae spread through highly vascularized tissues, including the brain. Most patients are asymptomatic, but in some cases, cysts can cause inflammation, which can lead to headaches, seizures, and intracranial hypertension. The preferred treatment for neurocysticercosis remains unclear: the combination therapy of albendazole plus praziquantel has been associated with greater benefits than albendazole alone.

Abstract
Review title:
Albendazole plus Praziquantel versus Albendazole Alone in the Treatment of Neurocysticercosis: A Systematic Review and Meta-Analysis
PICO:
P - patients with neurocysticercosis;
I - treatment with albendazole and praziquentel associated;
C - placebo, praziquentel alone or with an increased dose or albendazole alone or with an increased dose;
O - complete resolution of the cyst, adverse effects and recurrence of seizures;
T - observational or randomized;

Exclusion criteria:
alone albendazole or praziquantel used in the intervention group; absence of group control; non-English language; conference abstracts.

Searches:
We searched MEDLINE, Embase, and Cochrane Central Register of Controlled Trials from inception to May 11, 2024.
Search strategy: (combined OR combination) AND (praziquantel) AND (albendazole) AND (neurocysticercosis OR “brain cysticercosis”).

Data extraction:
Four authors independently (L.M.V., M.E.S., G.O.C, L.L.LS.) conducted data extraction, collecting the following information from each study: study population, number of patients, resolution of the cyst or damage, adverse events, seizure relapse and the use of other medications, such as anti-inflammatories and corticosteroids. No data conversion was required.

Endpoints:
The primary outcome was the resolution of the cyst or lesion. Secondary outcomes included the adverse effects of using the combination, such as headaches and seizure recurrence after treatment. In addition, it was analyzed to consider the use of other medications, like anti-inflammatories and corticosteroids.

Statistical Analysis::
We used R software version 4.3.2 (R Foundation for Statistical Computing) and the extension package “meta” for all statistical analyses. Studies were eligible for synthesis if data on each outcome were available. Binary outcomes were analyzed using odds ratio (OR) or risk ratio (RR). Statistical significance was set as p-values < 0,5. Heterogeneity was assessed using I² statistics, and significance was attributed to cases with I²>25%. For all outcomes, the Mantel-Haenszel random-effects model was applied.
Quality Assessment:
Assessment of risk of bias in individual studies was conducted using the Cochrane Risk of Bias tool for randomized trials. Two independent authors evaluated the bias risk of each study and documented their observations. Disagreements were resolved through discussion and consensus

Keywords:
neurocysticercosis, albendazole and praziquantel